Description
Product Characteristics:
Aliases: DKFZp686C01211 antibody, DNA binding factor KBF1 antibody, DNA binding factor KBF1 EBP1 antibody, DNA-binding factor KBF1 antibody, EBP 1 antibody, EBP-1 antibody, EBP1 antibody, KBF1 antibody, MGC54151 antibody, nf b antibody, NF kappa B antibody, NF kappaB antibody, NF kappabeta antibody, NF kB1 antibody, NF-kappaB antibody, NFkappaB antibody, NFKB 1 antibody, NFKB p105 antibody, NFKB p50 antibody, NFKB-p105 antibody, Nfkb1 antibody, NFKB1_HUMAN antibody, Nuclear factor kappa B DNA binding subunit antibody, Nuclear factor kappa-B antibody, Nuclear factor kappa-B, subunit 1 antibody, Nuclear factor NF kappa B p105 subunit antibody, Nuclear factor NF kappa B p50 subunit antibody, Nuclear factor NF-kappa-B p50 subunit antibody, Nuclear factor of kappa light chain gene enhancer in B cells 1 antibody, Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 antibody, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 antibody, p105 antibody, p50 antibody, p84/NF-kappa-B1 p98 antibody, Transcription factor NFKB1 antibody
Target Information: This gene encodes a 105 kD protein which can undergo cotranslational processing by the 26S proteasome to produce a 50 kD protein. The 105 kD protein is a Rel protein-specific transcription inhibitor and the 50 kD protein is a DNA binding subunit of the NF-kappa-B (NFKB) protein complex. NFKB is a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines, oxidant-free radicals, ultraviolet irradiation, and bacterial or viral products. Activated NFKB translocates into the nucleus and stimulates the expression of genes involved in a wide variety of biological functions. Inappropriate activation of NFKB has been associated with a number of inflammatory diseases while persistent inhibition of NFKB leads to inappropriate immune cell development or delayed cell growth. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2009]